Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$15.4 million.

  • Vistagen Therapeutics' Net Cash Flow fell 6173.54% to -$15.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$27.3 million, marking a year-over-year increase of 4725.24%. This contributed to the annual value of -$52.0 million for FY2025, which is 15075.49% down from last year.
  • Per Vistagen Therapeutics' latest filing, its Net Cash Flow stood at -$15.4 million for Q4 2025, which was down 6173.54% from $13.8 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Net Cash Flow peaked at $89.0 million during Q4 2023, and registered a low of -$18.7 million during Q3 2024.
  • Moreover, its 5-year median value for Net Cash Flow was -$9.5 million (2021), whereas its average is -$3.1 million.
  • As far as peak fluctuations go, Vistagen Therapeutics' Net Cash Flow crashed by 289423.48% in 2021, and later skyrocketed by 96783.29% in 2023.
  • Vistagen Therapeutics' Net Cash Flow (Quarter) stood at -$9.9 million in 2021, then fell by 3.25% to -$10.2 million in 2022, then surged by 967.83% to $89.0 million in 2023, then plummeted by 110.71% to -$9.5 million in 2024, then plummeted by 61.74% to -$15.4 million in 2025.
  • Its last three reported values are -$15.4 million in Q4 2025, $13.8 million for Q3 2025, and -$18.1 million during Q2 2025.